More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...

A recent survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

This fall, Fierce Pharma Marketing launched a running series of Q&A features celebrating up-and-comers in our corner of the ...

| Adopting an RTU vial setup for aseptic filling process can help optimize operational efficiency, reduce TCO, and comply ...

Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...

When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...

The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...